Teach me everything I need to know as an MBBS student in ANS Pharmacology
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Here is your complete MBBS-level ANS Pharmacology guide, synthesized from Lippincott Illustrated Reviews: Pharmacology and Katzung's Basic & Clinical Pharmacology.
🧠 ANS Pharmacology — Complete MBBS Guide
PART 1 — ANATOMY & PHYSIOLOGY REVIEW
Organization of the ANS
The ANS regulates involuntary visceral function — heart, smooth muscle, glands — without conscious control. It is also called the visceral, vegetative, or involuntary nervous system.
Two-neuron pathway:
- Preganglionic neuron → cell body in CNS → exits to a ganglion
- Postganglionic neuron → cell body in ganglion → innervates effector organ
| Feature | Sympathetic | Parasympathetic |
|---|---|---|
| Origin | Thoracolumbar (T1–L2) | Craniosacral (CN 3, 7, 9, 10 + S2–S4) |
| Ganglia location | Paravertebral / prevertebral chains (distant) | In/near target organ (close) |
| Pre:Post fiber ratio | 1:many (divergence) | 1:1 (discrete) |
| Primary NT (preganglionic) | ACh (nicotinic) | ACh (nicotinic) |
| Primary NT (postganglionic) | Norepinephrine | ACh (muscarinic) |
| Exceptions | Sweat glands & some vasodilators → ACh (muscarinic); Adrenal medulla → Epi/NE into blood | — |
Adrenal medulla = modified sympathetic ganglion. Receives preganglionic cholinergic fibers → secretes 80% epinephrine + 20% NE directly into blood.
Functional Effects (Fight-or-Flight vs Rest-and-Digest)
| Organ | Sympathetic Effect | Parasympathetic Effect |
|---|---|---|
| Heart rate | ↑ (β1) | ↓ (M2) |
| Heart contractility | ↑ (β1) | ↓ (atria only, M2) |
| Blood vessels (skin/viscera) | Constriction (α1) | — |
| Blood vessels (skeletal muscle) | Dilation (β2) | — |
| Bronchioles | Dilation (β2) | Constriction (M3) |
| GI motility | ↓ (α2, β2) | ↑ (M3) |
| GI sphincters | Contract (α1) | Relax (M3) |
| Pupils | Dilation — mydriasis (α1) | Constriction — miosis (M3) |
| Lens (ciliary muscle) | Relaxes → far vision (β2) | Contracts → near vision (M3) |
| Urinary bladder (detrusor) | Relaxes (β2) | Contracts (M3) |
| Urinary sphincter | Contracts (α1) | Relaxes (M3) |
| Salivary glands | Thick, scant secretion (α1) | Watery, profuse secretion (M3) |
| Sweat glands | Sweating (M — sympathetic cholinergic) | — |
| Ejaculation | Yes (α1) | Erection (M) |
| Liver | Glycogenolysis/gluconeogenesis (β2, α1) | Glycogen synthesis |
| Kidney | Renin release (β1) | — |
PART 2 — NEUROTRANSMITTER PHYSIOLOGY
Cholinergic Transmission (6 Steps)
- Synthesis: Choline + Acetyl-CoA → ACh (enzyme: choline acetyltransferase)
- Storage: Packaged into vesicles by VAChT (vesicular ACh transporter)
- Release: Action potential → Ca²⁺ influx → exocytosis
- Receptor binding: ACh binds muscarinic or nicotinic receptors
- Degradation: Acetylcholinesterase (AChE) cleaves ACh → choline + acetate in synaptic cleft
- Recycling: Choline taken back up into neuron by choline transporter
Key drug target: AChE inhibitors block step 5 → prolong ACh action
Adrenergic Transmission (4 Steps)
- Synthesis: Tyrosine → DOPA (rate-limiting step: tyrosine hydroxylase) → Dopamine → NE
- Storage: Dopamine transported into vesicles by VMAT (vesicular monoamine transporter) — blocked by reserpine
- Release: Action potential → Ca²⁺ influx → exocytosis
- Termination:
- Reuptake (Uptake-1) into neuron — major mechanism — blocked by cocaine, TCAs
- MAO (intraneuronal) — degrades NE
- COMT (extraneuronal/synaptic cleft) — methylates catecholamines
- Final metabolite: VMA (vanillylmandelic acid) — excreted in urine (useful in diagnosing pheochromocytoma)
PART 3 — RECEPTORS
Cholinergic Receptors
| Receptor | Type | Location | Effect |
|---|---|---|---|
| Nicotinic (NM) | Ion channel (Na⁺/K⁺) | Neuromuscular junction | Skeletal muscle contraction |
| Nicotinic (NN) | Ion channel | Autonomic ganglia, adrenal medulla, CNS | Fast EPSP, ganglion activation |
| Muscarinic M1 | Gq → IP3/DAG | CNS, gastric parietal cells | ↑ cognition, ↑ gastric acid |
| Muscarinic M2 | Gi → ↓cAMP | Heart (SA/AV node) | ↓ HR, ↓ AV conduction |
| Muscarinic M3 | Gq → IP3/DAG | Smooth muscle, glands, eye | Contraction, secretion, miosis |
Mnemonic: M1 = CNS/stomach; M2 = heart ("2 = two-pump organ"); M3 = smooth muscle/glands ("3 = three systems")
Adrenergic Receptors (Adrenoceptors)
| Receptor | G-protein | Second Messenger | Location | Effect |
|---|---|---|---|---|
| α1 | Gq | ↑IP3/DAG → ↑Ca²⁺ | Vascular smooth muscle, iris, prostate, bladder sphincter | Vasoconstriction, mydriasis, urinary retention |
| α2 | Gi | ↓cAMP | Presynaptic nerve terminals, CNS, pancreatic β-cells | ↓NE release (autoreceptor), ↓insulin, sedation |
| β1 | Gs | ↑cAMP | Heart, kidney (JGA) | ↑HR, ↑contractility, ↑renin |
| β2 | Gs | ↑cAMP | Bronchi, uterus, skeletal muscle vessels, liver | Bronchodilation, uterine relaxation, vasodilation |
| β3 | Gs | ↑cAMP | Adipose tissue, bladder detrusor | Lipolysis, bladder relaxation |
| D1 | Gs | ↑cAMP | Renal/mesenteric vasculature | Vasodilation |
| D2 | Gi | ↓cAMP | Presynaptic adrenergic neurons | ↓NE release |
Agonist potency ranking:
- α receptors: Epi ≥ NE >> Isoproterenol
- β receptors: Isoproterenol > Epi > NE
PART 4 — CHOLINERGIC DRUGS
A. Direct-Acting Cholinergic Agonists
Choline Esters
| Drug | Route | Selectivity | Key Uses |
|---|---|---|---|
| Acetylcholine | Ophthalmic (intraocular) | M + N | Miosis during ocular surgery |
| Bethanechol | Oral, SC | M only | Urinary retention (post-op, neurogenic bladder), ↑GI motility. Not hydrolyzed by AChE |
| Carbachol | Ophthalmic | M + N | Glaucoma, miosis in surgery |
| Methacholine | Inhaled | M only | Bronchoprovocation test for asthma diagnosis |
Bethanechol key fact: Selective M agonist, resistant to AChE → preferred for GI/urinary use. CI in asthma, peptic ulcer, obstruction.
Alkaloids
| Drug | Key Uses | Notes |
|---|---|---|
| Pilocarpine | Glaucoma (reduces IOP), Sjögren syndrome (dry mouth/eyes), xerostomia | Penetrates CNS; most important ophthalmic cholinergic |
| Nicotine | Smoking cessation | Low dose → ganglionic stimulation; High dose → ganglionic block (depolarization block) |
| Muscarine | Mushroom poisoning (Clitocybe, Inocybe) | No therapeutic use |
| Cevimeline | Sjögren syndrome | Longer acting than pilocarpine |
B. Indirect-Acting Cholinergic Agonists (AChE Inhibitors)
Reversible AChE Inhibitors
| Drug | CNS penetration | Duration | Key Uses | Notes |
|---|---|---|---|---|
| Physostigmine | Yes | Short | Atropine/anticholinergic overdose | Natural alkaloid; tertiary N |
| Neostigmine | No (quaternary N) | 30 min–2 hr | Myasthenia gravis, reverse NMB, post-op urinary/GI atony | Greater NMJ effect than physostigmine |
| Pyridostigmine | No | 3–6 hr | Chronic myasthenia gravis management | Longer acting than neostigmine |
| Edrophonium | No | Very short (5–10 min) | Tensilon test — diagnosis of myasthenia gravis | No carbamylation; electrostatic binding only |
| Donepezil | Yes | Long (24 hr) | Alzheimer disease | Selective CNS AChE inhibitor |
| Rivastigmine | Yes | Intermediate | Alzheimer, Parkinson dementia | Also inhibits butyrylcholinesterase |
| Galantamine | Yes | — | Alzheimer disease | Also allosterically potentiates nicotinic receptors |
| Tacrine | Yes | — | Alzheimer (obsolete) | Withdrawn due to hepatotoxicity |
Irreversible AChE Inhibitors (Organophosphates)
| Drug | Uses |
|---|---|
| Echothiophate | Glaucoma (ophthalmic drops) |
| Sarin, VX, Tabun | Chemical warfare agents |
| Malathion, Parathion | Agricultural insecticides |
Mechanism: Form covalent bond with AChE serine → "aging" if not treated promptly (permanent inactivation)
Organophosphate poisoning features (SLUDGE + DUMBELS):
- Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis
- Diaphoresis, Urination, Miosis, Bradycardia, Bronchospasm/bronchorrhea, Emesis, Lacrimation, Salivation
- Muscle fasciculations → weakness → paralysis (NMJ overactivation)
- CNS: anxiety, seizures, coma
Treatment of OP poisoning:
- Atropine — blocks muscarinic effects (high doses needed) — endpoint is drying of secretions
- Pralidoxime (2-PAM) — reactivates AChE before aging occurs (within ~24–48 hours); does NOT reverse CNS effects (quaternary, can't cross BBB)
- Benzodiazepines — for seizures
PART 5 — ANTICHOLINERGIC DRUGS (Muscarinic Antagonists)
Antimuscarinic Agents — Overview
These block M receptors only (not nicotinic), leaving sympathetic tone unopposed.
Classic mnemonic for atropine effects:
"Hot as a hare, Dry as a bone, Red as a beet, Blind as a bat, Mad as a hatter, Full as a flask"
| Effect | Explanation |
|---|---|
| ↑ Heart rate (tachycardia) | Block M2 on SA node |
| ↓ Secretions (dry mouth, anhidrosis) | Block M3 on glands |
| Mydriasis + cycloplegia | Block M3 on iris/ciliary muscle |
| Constipation, urinary retention | Block M3 on GI/bladder |
| CNS effects (confusion, hallucinations) | With tertiary amines that cross BBB |
| Flushing (vasodilation) | Mechanism unclear, possibly loss of cholinergic vasodilation in skin |
Key Antimuscarinics
| Drug | Properties | Uses |
|---|---|---|
| Atropine | Tertiary amine, crosses BBB, non-selective M blocker | Bradycardia, organophosphate poisoning, pre-anesthetic (dry secretions), ophthalmic (mydriasis, cycloplegia), antidiarrheal |
| Scopolamine | Tertiary, strong CNS effects | Motion sickness (transdermal patch), pre-anesthetic, short-term amnesia |
| Ipratropium | Quaternary (no CNS effects), inhaled | COPD (bronchodilation), rhinorrhea |
| Tiotropium | Quaternary, long-acting (24 hr), inhaled | COPD (maintenance) |
| Glycopyrrolate | Quaternary, no CNS effects | Pre-anesthetic, peptic ulcer, hyperhidrosis |
| Benztropine / Trihexyphenidyl | Tertiary, CNS active | Parkinson disease (reduces tremor/rigidity) |
| Oxybutynin / Tolterodine / Solifenacin | Selective M3 blockers | Overactive bladder (OAB) |
| Darifenacin | M3 selective | OAB (less cognitive side effects) |
| Tropicamide / Cyclopentolate | Short acting | Ophthalmic (mydriasis/refraction) |
CI for antimuscarinics: Angle-closure glaucoma, BPH, myasthenia gravis, paralytic ileus
Ganglionic Blockers
- Mecamylamine, Trimethaphan — Block NN receptors at ganglia
- Rarely used clinically; historically for hypertensive emergencies
- Block BOTH sympathetic and parasympathetic ganglia → unpredictable effects
Neuromuscular Blocking Agents (NMJ Blockers)
| Type | Drugs | Mechanism | Reversal |
|---|---|---|---|
| Depolarizing | Succinylcholine | Persistent activation of NM nicotinic receptor → depolarization block; Phase I → Phase II block | No pharmacologic reversal; succinylcholinesterase (plasma ChE) hydrolyzes it |
| Non-depolarizing (competitive) | Rocuronium, Vecuronium, Pancuronium, Cisatracurium, Mivacurium | Competitive block of NM nicotinic receptor | Neostigmine (+ atropine to prevent bradycardia), or Sugammadex (for rocuronium/vecuronium) |
Succinylcholine contraindications: Burns, crush injury, hyperkalemia risk, pseudocholinesterase deficiency (prolonged apnea), malignant hyperthermia (with volatile anesthetics)
PART 6 — ADRENERGIC DRUGS
A. Adrenergic Agonists (Sympathomimetics)
Classification:
- Direct-acting — bind adrenoceptors directly
- Indirect-acting — stimulate NE release or block reuptake
- Mixed-acting — both direct and indirect (e.g., ephedrine)
Catecholamines (direct-acting)
Cannot cross BBB (polar); not orally active (metabolized by MAO/COMT); short duration
| Drug | α1 | α2 | β1 | β2 | Key Uses |
|---|---|---|---|---|---|
| Epinephrine | +++ | ++ | +++ | +++ | Anaphylaxis (1st line), cardiac arrest (ACLS), adjunct to local anesthetics (prolongs action), acute asthma (SC) |
| Norepinephrine | +++ | ++ | ++ | 0 | Septic shock (vasopressor), ↑BP. Causes reflex bradycardia (baroreceptor) |
| Dopamine | ++ (high dose) | — | ++ | — | Shock: D1 (renal vasodilation, low dose), β1 (inotropy, moderate dose), α1 (vasoconstriction, high dose) |
| Isoproterenol | 0 | 0 | +++ | +++ | Heart block, bronchospasm (historical); tachycardia limits use |
| Dobutamine | 0 | 0 | +++ (selective) | + | Acute heart failure (↑cardiac output without major ↑HR or BP) |
Non-catecholamine Sympathomimetics
| Drug | Type | Uses | Notes |
|---|---|---|---|
| Phenylephrine | Direct α1 | Nasal decongestant, hypotension (intraoperative), mydriasis | No β effects → causes reflex bradycardia |
| Clonidine | Direct α2 (central) | Hypertension, ADHD, opioid/alcohol withdrawal, menopausal flushing | Reduces sympathetic outflow from CNS; rebound hypertension on abrupt withdrawal |
| α-Methyldopa | Indirect α2 (central) | Hypertension in pregnancy (drug of choice) | Converted to α-methylNE → stimulates central α2 |
| Albuterol (Salbutamol) | Direct β2 | Acute asthma (rescue), COPD | Short-acting β2 agonist (SABA); inhaled |
| Salmeterol / Formoterol | Direct β2 | COPD and asthma (maintenance) | Long-acting β2 agonists (LABA); black box warning: do not use as monotherapy in asthma — increased asthma-related deaths |
| Terbutaline / Ritodrine | Direct β2 | Tocolysis (suppress premature labor) | Uterine relaxation via β2 |
| Ephedrine | Mixed (α + β) | Nasal decongestant, hypotension during spinal anesthesia, asthma (historical) | Releases stored NE + direct action; crosses BBB; tachyphylaxis |
| Pseudoephedrine | Mixed | Nasal decongestant (oral OTC) | Precursor for illicit methamphetamine synthesis → regulated OTC |
| Amphetamine | Indirect | ADHD, narcolepsy | Reverses VMAT + DAT → massive NE/DA release; CNS stimulant |
| Cocaine | Indirect | Topical local anesthetic (ENT) | Blocks reuptake (Uptake-1); vasoconstriction → useful in nasal surgery |
Dopamine dose-effect summary (clinical pearl):
- Low (1–5 mcg/kg/min): D1 → renal & mesenteric vasodilation
- Moderate (5–10 mcg/kg/min): β1 → ↑cardiac output
- High (>10 mcg/kg/min): α1 → vasoconstriction
B. Adrenergic Antagonists (Sympatholytics)
α-Blockers
| Drug | Selectivity | Reversibility | Uses |
|---|---|---|---|
| Phentolamine | α1 + α2 (non-selective) | Reversible | Pheochromocytoma diagnosis/preoperative management, extravasation of NE/dopamine |
| Phenoxybenzamine | α1 + α2 (non-selective) | Irreversible (covalent) | Pheochromocytoma (pre-op) |
| Prazosin | α1 selective | Reversible | Hypertension, BPH; first-dose syncope |
| Doxazosin / Terazosin | α1 selective | Reversible | BPH, hypertension; once daily |
| Tamsulosin | α1A selective (urogenital) | Reversible | BPH (minimal BP effect) |
| Yohimbine | α2 selective | Reversible | Research tool; sexual dysfunction (historical) |
Epinephrine reversal (adrenaline reversal): Phentolamine (α-blocker) administered before epinephrine → epinephrine's α effects are blocked, leaving only β2 vasodilation → BP falls instead of rises. Classic pharmacology exam question.
β-Blockers
All β-blockers are competitive antagonists. Names end in "-olol" (except labetalol, carvedilol).
| Drug | Selectivity | ISA | Other | Uses |
|---|---|---|---|---|
| Propranolol | Non-selective (β1+β2) | No | Membrane stabilizing | Hypertension, angina, arrhythmias, MI, thyrotoxicosis, tremor, migraine prophylaxis, portal hypertension |
| Metoprolol | β1 selective | No | — | Hypertension, heart failure, MI (cardioprotective) |
| Atenolol | β1 selective | No | — | Hypertension, angina, MI |
| Esmolol | β1 selective | No | Ultra-short acting (t½ = 9 min) | Intraoperative/perioperative tachycardia, SVT |
| Timolol | Non-selective | No | Ophthalmic | Glaucoma (↓aqueous humor production) |
| Nadolol | Non-selective | No | Long acting | Hypertension, angina |
| Pindolol | Non-selective | Yes | ISA means partial agonism | Hypertension (less bradycardia) |
| Labetalol | α1 + β (non-selective) | No | Also blocks α1 | Hypertension in pregnancy, hypertensive emergencies |
| Carvedilol | α1 + β (non-selective) | No | Antioxidant properties | Heart failure (reduces mortality), hypertension |
| Nebivolol | β1 selective | — | Releases NO → vasodilation | Hypertension |
| Celiprolol | β1 selective, β2 partial agonist | Yes | — | Hypertension |
β-Blocker adverse effects:
- Bradycardia, AV block, ↓cardiac output
- Bronchoconstriction (β2 block) — CI in asthma/COPD (use cardioselective if must)
- Masking hypoglycemia symptoms (CI in brittle diabetics)
- Fatigue, cold extremities, sexual dysfunction
- Abrupt withdrawal → rebound tachycardia, angina, MI — always taper
- Metabolic: ↑triglycerides, ↑LDL (except carvedilol)
β-Blocker contraindications:
- Asthma / reactive airways (relative)
- Decompensated heart failure (acute)
- Bradycardia/AV block (2nd/3rd degree)
- Cocaine-induced chest pain (β-block leaves α vasospasm unopposed → use phentolamine instead)
Mixed α/β Blockers
- Labetalol — IV for hypertensive emergencies, hypertension in pregnancy
- Carvedilol — Chronic heart failure, post-MI LV dysfunction
PART 7 — HIGH-YIELD COMPARISONS & EXAM PEARLS
Effect of Key Drugs on Heart Rate
| Drug | Mechanism | Net HR Effect |
|---|---|---|
| Epinephrine (low dose) | β1 dominates | ↑ HR |
| Epinephrine (high dose) | α1 → ↑BP → baroreceptor reflex | Slight ↓ HR or unchanged |
| Norepinephrine | α1 → ↑BP → strong baroreceptor reflex | ↓ HR (reflex bradycardia) |
| Phenylephrine | α1 only → ↑BP → baroreceptor reflex | ↓ HR (reflex bradycardia) |
| Isoproterenol | β1 (direct) + β2 → ↓BP (vasodilation) | ↑↑ HR (direct + reflex) |
| Atropine | Blocks M2 on SA node | ↑ HR |
| Neostigmine | ↑ACh → M2 activation | ↓ HR |
Drug of Choice Summary
| Condition | Drug |
|---|---|
| Anaphylaxis | Epinephrine (IM, 1:1000) |
| Septic shock (vasopressor) | Norepinephrine |
| Acute decompensated heart failure | Dobutamine |
| Asthma attack (acute) | Salbutamol (inhaled SABA) |
| Asthma + COPD maintenance | LABA + inhaled corticosteroid |
| Tocolysis (preterm labor) | Terbutaline or ritodrine |
| Hypertension in pregnancy | Methyldopa / Labetalol |
| Pheochromocytoma (pre-op) | Phenoxybenzamine (irreversible α-blocker) |
| BPH + hypertension | Doxazosin/Prazosin |
| BPH only (no BP effect needed) | Tamsulosin |
| Myasthenia gravis (diagnosis) | Edrophonium (Tensilon test) |
| Myasthenia gravis (treatment) | Pyridostigmine |
| Alzheimer disease | Donepezil (1st line AChE inhibitor) |
| Organophosphate poisoning | Atropine + Pralidoxime |
| Glaucoma (open angle) | Pilocarpine, Timolol, Latanoprost |
| Motion sickness | Scopolamine (transdermal) |
| COPD (inhaled anticholinergic) | Tiotropium |
| Overactive bladder | Oxybutynin, Tolterodine, Solifenacin |
| Parkinson tremor/rigidity | Benztropine/Trihexyphenidyl |
| Reversal of NMB (non-depolarizing) | Neostigmine + Atropine |
| Reversal of Rocuronium | Sugammadex (preferred) |
Receptor Summary for Catecholamines
| α1 | α2 | β1 | β2 | |
|---|---|---|---|---|
| Epinephrine | ++++ | +++ | ++++ | ++++ |
| Norepinephrine | ++++ | +++ | ++ | 0/+ |
| Dopamine | + (high dose) | — | ++ | — |
| Isoproterenol | 0 | 0 | ++++ | ++++ |
| Dobutamine | 0 | 0 | ++++ | + |
| Phenylephrine | +++ | 0 | 0 | 0 |
| Clonidine | 0 | ++++ | 0 | 0 |
| Albuterol | 0 | 0 | 0 | ++++ |
PART 8 — CLINICAL SCENARIOS (Exam-Focused)
Q: Patient with asthma gets propranolol — what happens?
β2 block → bronchoconstriction → dangerous. Use cardioselective β1 blocker (metoprolol) if absolutely necessary.
Q: NE infusion extravasates into arm tissue — treatment?
Phentolamine (α-blocker) injected locally to reverse vasoconstriction and prevent necrosis.
Q: Farmer presents with SLUDGE, miosis, bradycardia after pesticide exposure:
Organophosphate poisoning → Atropine (large doses to dry secretions) + Pralidoxime (if given early).
Q: Patient on MAO inhibitors takes ephedrine — dangerous?
MAO inhibition → NE not degraded intraneuronally → ephedrine releases massive NE stores → hypertensive crisis.
Q: Cocaine + β-blocker in chest pain — why dangerous?
β-block leaves α (vasoconstriction) unopposed → worsens coronary spasm. Use phentolamine or benzodiazepines instead.
Q: Edrophonium test — patient's weakness improves — diagnosis?
Myasthenia gravis (anti-AChR antibody disease). Weakness improves because more ACh is available at NMJ.
Q: Why does atropine cause tachycardia but physostigmine causes bradycardia?
Atropine blocks M2 (vagal control) → ↑HR. Physostigmine inhibits AChE → ↑ACh → M2 activation → ↓HR.
PART 9 — MEMORY AIDS
| Mnemonic | What it covers |
|---|---|
| SLUDGE / DUMBELS | Organophosphate / cholinergic excess signs |
| "Hot as a hare, Dry as a bone..." | Atropine toxicity effects |
| "-olol" suffix | All β-blockers |
| "α1 constricts, α2 inhibits, β1 beats, β2 breathes/babies" | Receptor actions |
| "Fight or flight" vs "Rest and digest" | Sympathetic vs parasympathetic |
| Dopamine: D-M-H (Dilate-Moderate-High) | Low dose D1 (dilate), Mid β1 (heart), High α1 (hypertension) |
| "PINCH" for β-blockers CI | Pulmonary (asthma), Insulin-masking, No (AV block), Cocaine, Heart failure (decompensated) |
Sources: Lippincott Illustrated Reviews: Pharmacology, 8e · Katzung's Basic & Clinical Pharmacology, 16e · Guyton & Hall Medical Physiology
This covers the entire MBBS ANS pharmacology syllabus: anatomy/physiology of the ANS, cholinergic/adrenergic neurotransmission, all receptor types with second messengers, every drug class with mechanisms/uses/adverse effects, and exam-ready clinical scenarios. Let me know if you want any section expanded — for example, a deep-dive into β-blockers in heart failure, or a topic-wise MCQ drill.
Teach me everything I need to know as an MBBS student in CNS Pharmacology
Checking Date & Time
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.